User login
Key clinical point: A brief group education and supportive self-management program had no beneficial effects on clinically relevant outcomes in patients with chronic migraine or chronic tension type headache and episodic migraine, with or without medication overuse headache.
Major finding: At 12 months, Headache Impact Test scores (adjusted mean difference [AMD] −0.3; P = .56), number of headache days (AMD 0.2; P = .234), duration of headache (estimated difference [ED] 0.4; P = .361), and headache severity (ED 0.2; P = .163) were not significantly different between patients who received self-management intervention vs usual care.
Study details: The data come from CHESS, a randomized controlled trial, including 727 participants with chronic migraine or chronic tension type headache and episodic migraine, with or without medication overuse headache, who received self-management intervention or usual care.
Disclosures: This study was funded by the UK National Institute for Health Research Programme Grants for Applied Research program. Several authors reported receiving grants, personal fees, or honoraria from various sources or owning patent.
Source: Underwood M et al. A supportive self-management program for people with chronic headaches and migraine: A randomized controlled trial and economic evaluation. Neurology. 2022 (Dec 16). Doi: 10.1212/WNL.0000000000201518
Key clinical point: A brief group education and supportive self-management program had no beneficial effects on clinically relevant outcomes in patients with chronic migraine or chronic tension type headache and episodic migraine, with or without medication overuse headache.
Major finding: At 12 months, Headache Impact Test scores (adjusted mean difference [AMD] −0.3; P = .56), number of headache days (AMD 0.2; P = .234), duration of headache (estimated difference [ED] 0.4; P = .361), and headache severity (ED 0.2; P = .163) were not significantly different between patients who received self-management intervention vs usual care.
Study details: The data come from CHESS, a randomized controlled trial, including 727 participants with chronic migraine or chronic tension type headache and episodic migraine, with or without medication overuse headache, who received self-management intervention or usual care.
Disclosures: This study was funded by the UK National Institute for Health Research Programme Grants for Applied Research program. Several authors reported receiving grants, personal fees, or honoraria from various sources or owning patent.
Source: Underwood M et al. A supportive self-management program for people with chronic headaches and migraine: A randomized controlled trial and economic evaluation. Neurology. 2022 (Dec 16). Doi: 10.1212/WNL.0000000000201518
Key clinical point: A brief group education and supportive self-management program had no beneficial effects on clinically relevant outcomes in patients with chronic migraine or chronic tension type headache and episodic migraine, with or without medication overuse headache.
Major finding: At 12 months, Headache Impact Test scores (adjusted mean difference [AMD] −0.3; P = .56), number of headache days (AMD 0.2; P = .234), duration of headache (estimated difference [ED] 0.4; P = .361), and headache severity (ED 0.2; P = .163) were not significantly different between patients who received self-management intervention vs usual care.
Study details: The data come from CHESS, a randomized controlled trial, including 727 participants with chronic migraine or chronic tension type headache and episodic migraine, with or without medication overuse headache, who received self-management intervention or usual care.
Disclosures: This study was funded by the UK National Institute for Health Research Programme Grants for Applied Research program. Several authors reported receiving grants, personal fees, or honoraria from various sources or owning patent.
Source: Underwood M et al. A supportive self-management program for people with chronic headaches and migraine: A randomized controlled trial and economic evaluation. Neurology. 2022 (Dec 16). Doi: 10.1212/WNL.0000000000201518